首页> 外文期刊>BMJ Open >Study protocol for a single-centre, prospective, non-blinded, randomised, 12-month, parallel-group superiority study to compare the efficacy of pharmacist intervention versus usual care for elderly patients hospitalised in orthopaedic wards
【24h】

Study protocol for a single-centre, prospective, non-blinded, randomised, 12-month, parallel-group superiority study to compare the efficacy of pharmacist intervention versus usual care for elderly patients hospitalised in orthopaedic wards

机译:一项针对单中心,前瞻性,无盲,随机,12个月,平行组的优势研究的研究方案,以比较药剂师干预与常规护理对在骨科病房住院的老年患者的疗效

获取原文
           

摘要

Introduction Given that polypharmacy and potentially inappropriate prescribing are common in elderly orthopaedic patients, pharmacist interventions to improve medication practices among this population are important. However, past studies have reported mixed results regarding the effectiveness of pharmacist-led interventions in inpatient elderly care. Furthermore, few randomised controlled trials have evaluated patient-relevant outcomes as a primary endpoint. Therefore, we will evaluate whether a pharmacist-led intervention could reduce readmission of hospitalised elderly orthopaedic patients with polypharmacy or potentially inappropriate prescribing.Methods and analysis This is an ongoing single-centre, prospective, non-blinded, randomised controlled trial designed to evaluate the superiority of a pharmacist-led intervention for hospitalised elderly patients compared with usual care. The trial will include newly admitted orthopaedic patients 70 years of age and older with polypharmacy or at least one potentially inappropriate prescription, as identified by the screening tool of older people’s prescriptions (STOPP) criteria. Usual care includes medication reconciliation, patient education and monitoring, as well as providing information about discharge medications. Pharmacist interventions, in addition to usual care, include advising the patient’s physician to stop unnecessary or inappropriate medications and start necessary medications. The primary outcome is the 1-year readmission rate. Secondary outcomes are the proportion of patients who undergo emergency department visits and the occurrences of all-cause death, a new fracture, myocardial infarction and ischaemic stroke. The study started in November 2017, and up to approximately 220 patients will be enrolled.Ethics and dissemination The protocol was approved by the Medical Ethics Committee of the National Hospital Organization Tochigi Medical Center (No. 29–22). The trial was registered at the University Hospital Medical Information Network (UMIN) clinical registry. The results of this trial will be submitted for publication in a peer-reviewed journal.Trial registration number UMIN000029404.
机译:简介鉴于在老年骨科患者中普遍存在多药房开药和可能不适当的开处方的情况,因此药师采取干预措施以改善该人群的用药习惯非常重要。但是,过去的研究报告了关于由药剂师主导的干预措施在住院老年护理中的有效性的好坏参半的结果。此外,很少有随机对照试验将患者相关结局作为主要终点。因此,我们将评估由药剂师主导的干预措施是否可以减少因多药治疗或可能存在不适当处方而住院的老年骨科患者的再入院。与常规护理相比,药剂师主导的住院老年患者干预的优势。该试验将包括70岁及以上的新入院的骨科患者,这些患者具有综合药房或至少一种可能不合适的处方,这是通过老年人处方(STOPP)标准的筛选工具确定的。通常的护理包括药物调和,患者教育和监测,以及提供有关出院药物的信息。除常规护理外,药剂师的干预措施还包括建议患者的医生停止不必要或不合适的药物并开始必要的药物治疗。主要结局是一年的再入院率。次要结果是急诊科就诊患者的比例以及全因死亡,新骨折,心肌梗塞和缺血性中风的发生率。该研究于2017年11月开始,最多将招募220名患者。伦理与传播该方案已由美国国家医院组织Organization木医学中心的医学伦理委员会批准(编号29-22)。该试验已在大学医院医学信息网络(UMIN)临床注册中心进行了注册。该试验的结果将提交至同行评审的期刊上发表,试验注册号为UMIN000029404。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号